TRUST-II: A global phase II study for taletrectinib in <i>ROS1</i> fusion–positive lung cancer and other solid tumors.Misako Nagasaka, Yuichiro Ohe, Chang‐Min Choi et al.|Journal of Clinical Oncology|2022Cited by 4